Low quality antibody responses in critically ill patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
16
05
2022
accepted:
23
08
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Although some adults infected with influenza 2009 A(H1N1)pdm09 viruses mounted high hemagglutination inhibition (HAI) antibody response, they still suffered from severe disease, or even death. Here, we analyzed antibody profiles in patients (n = 31, 17-65 years) admitted to intensive care units (ICUs) with lung failure and invasive mechanical ventilation use due to infection with A(H1N1)pdm09 viruses during 2009-2011. We performed a comprehensive analysis of the quality and quantity of antibody responses using HAI, virus neutralization, biolayer interferometry, enzyme-linked-lectin and enzyme-linked immunosorbent assays. At time of the ICU admission, 45% (14/31) of the patients had HAI antibody titers ≥ 80 in the first serum (S1), most (13/14) exhibited narrowly-focused HAI and/or anti-HA-head binding antibodies targeting single epitopes in or around the receptor binding site. In contrast, 42% (13/31) of the patients with HAI titers ≤ 10 in S1 had non-neutralizing anti-HA-stem antibodies against A(H1N1)pdm09 viruses. Only 19% (6/31) of the patients showed HA-specific IgG1-dominant antibody responses. Three of 5 fatal patients possessed highly focused cross-type HAI antibodies targeting the (K130 + Q223)-epitopes with extremely low avidity. Our findings suggest that narrowly-focused low-quality antibody responses targeting specific HA-epitopes may have contributed to severe infection of the lower respiratory tract.
Identifiants
pubmed: 36056075
doi: 10.1038/s41598-022-18977-0
pii: 10.1038/s41598-022-18977-0
pmc: PMC9440095
doi:
Substances chimiques
Antibodies, Viral
0
Epitopes
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14971Informations de copyright
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Front Immunol. 2021 Oct 28;12:770066
pubmed: 34777390
J Infect Dis. 1999 Oct;180(4):1356-60
pubmed: 10479172
JAMA. 2009 Nov 4;302(17):1872-9
pubmed: 19822627
J Clin Invest. 1945 Jul;24(4):547-53
pubmed: 16695244
Curr Opin Virol. 2017 Jun;24:60-69
pubmed: 28527859
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Curr Opin Virol. 2017 Feb;22:105-111
pubmed: 28088686
Immunity. 2018 Jan 16;48(1):174-184.e9
pubmed: 29343437
Nat Med. 2011 Feb;17(2):195-9
pubmed: 21131958
J Virol Methods. 2014 Dec 15;210:7-14
pubmed: 25233882
Vaccine. 2017 Jan 3;35(1):191-198
pubmed: 27789145
Cell Host Microbe. 2017 Jun 14;21(6):742-753.e8
pubmed: 28618270
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33298562
Sci Transl Med. 2013 Aug 28;5(200):200ra114
pubmed: 23986398
Virology. 2014 Apr;454-455:169-75
pubmed: 24725943
J Virol. 2018 Sep 12;92(19):
pubmed: 30045982
Clin Exp Immunol. 1985 Apr;60(1):130-8
pubmed: 2988830
Clin Vaccine Immunol. 2010 Sep;17(9):1407-16
pubmed: 20660137
Front Immunol. 2019 Mar 22;10:553
pubmed: 30984170
Cell. 2016 Jul 28;166(3):596-608
pubmed: 27453466
Nature. 2012 Sep 27;489(7417):526-32
pubmed: 22982990
J Exp Med. 2011 Jan 17;208(1):181-93
pubmed: 21220454
J Infect Dis. 2015 Oct 15;212(8):1191-9
pubmed: 25858957
J Virol. 2011 Oct;85(20):10905-8
pubmed: 21849447
Influenza Other Respir Viruses. 2013 May;7(3):480-90
pubmed: 23122228
Am J Pathol. 2015 Jun;185(6):1528-36
pubmed: 25747532
Nat Med. 2014 Feb;20(2):143-51
pubmed: 24412922
Immunol Cell Biol. 2020 Apr;98(4):276-286
pubmed: 31785006
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-9
pubmed: 28332900
J Infect Dis. 2018 Mar 13;217(7):1078-1088
pubmed: 29342251
J Clin Virol. 2014 Aug;60(4):367-73
pubmed: 24930707
J Virol. 2010 Mar;84(6):3127-30
pubmed: 20042511
Trends Immunol. 2019 Mar;40(3):197-211
pubmed: 30745265
mBio. 2016 Oct 4;7(5):
pubmed: 27703076
J Virol. 2013 Nov;87(22):12471-80
pubmed: 24027321
Sci Rep. 2017 Dec 18;7(1):17735
pubmed: 29255273
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
Lancet. 2017 Aug 12;390(10095):697-708
pubmed: 28302313
J Infect Dis. 2018 Oct 5;218(10):1571-1581
pubmed: 29931203
Antibodies (Basel). 2019 Dec 05;8(4):
pubmed: 31817406
Front Cell Infect Microbiol. 2021 Mar 17;11:638852
pubmed: 33816341
mBio. 2012 May 29;3(3):
pubmed: 22647789
J Infect Dis. 2016 Dec 15;214(12):1947-1951
pubmed: 27923954
J Clin Invest. 1945 Jul;24(4):536-46
pubmed: 16695243
J Clin Microbiol. 2011 Jun;49(6):2210-5
pubmed: 21471339
Lancet Infect Dis. 2012 Sep;12(9):687-95
pubmed: 22738893
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199
pubmed: 31296560
Front Immunol. 2019 Mar 18;10:440
pubmed: 30949165
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
J Exp Med. 2013 Jul 29;210(8):1493-500
pubmed: 23857983
J Mol Biol. 2017 Aug 18;429(17):2694-2709
pubmed: 28648617
Front Endocrinol (Lausanne). 2020 Oct 06;11:556962
pubmed: 33123087
Hum Vaccin Immunother. 2018;14(11):2728-2736
pubmed: 29985756
Viruses. 2020 Mar 01;12(3):
pubmed: 32121563